Dongkook Pharmaceutical stock: two Madeca Cream Patch products
Published on 11/10/2026 at 04:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNew Skin-Care Products Expand Portfolio
- Dongkook Pharmaceutical launched two cream-based spot-care products for blemish and skin-tone concerns.
- The products are applied as a cream and peeled off after hardening, addressing limits of conventional adhesive patches.
- The launch extends Dongkook's consumer-healthcare portfolio alongside its pharmaceutical and established healthcare brands.
Dongkook Pharmaceutical launched two Madeca Cream Patch products on November 2, adding a cream-based spot-care format to its consumer-healthcare portfolio, according to the company's announcement.
A Peel-Off Alternative To Adhesive Patches
The products are applied directly to areas of concern and peeled off after the cream hardens. Dongkook said the format allows users to choose the size and thickness of the application and can be used after other skin-care products, addressing limits associated with conventional adhesive patches.
Madeca Cream Patch AcQ is intended for early blemish and sebum care. Dongkook said a human-use test on acne-prone skin found a 38.14 percent improvement in sebum-control results after four weeks.
Madeca Cream Patch WhiteQ is designed for skin-tone care on the face and on contoured areas such as elbows and knees. The company said testing showed a skin-tone improvement after one use. Both products completed low-irritation and skin-soothing tests, according to the release.
Portfolio Adds Consumer-Care Reach
The launch broadens Dongkook's consumer-facing offering beyond established pharmaceutical and health brands. For investors, the product adds another cosmetics-related item to the company's mix, although the announcement does not provide sales guidance or financial targets for the line.
Business Model And Market Position
Dongkook Pharmaceutical develops and sells prescription and over-the-counter medicines, consumer-health products and cosmetics, including the Madeca and Insadol brands. Its headquarters are in Seoul, South Korea, and its portfolio is aimed at the domestic healthcare market as well as export markets, including Europe. The company presents itself as a diversified healthcare business spanning medicines, personal care and research-driven product development.
Dongkook Pharmaceutical At A Glance
- Company: Dongkook Pharmaceutical
- ISIN: KR7086450004
- Headquarters: Seoul, South Korea
- Latest announcement: Two Madeca Cream Patch products launched on November 2, 2026
South Korean equities trade in the KOSPI market environment.
Read more news and analyses on Dongkook Pharmaceutical stock.
The product details are from the Dongkook Pharmaceutical announcement dated November 2, 2026.
